Identifying novel chemical matter against the Chikungunya virus nsP3 macrodomain through crystallographic fragment screening

• Published in: bioRxiv
• Main Authors: Aschenbrenner, Jasmin C, de Godoy, Andre Schutzer, Fairhead, Michael, Tomlinson, Charles W E, Winokan, Max, Balcomb, Blake H, Capkin, Eda, Chandran, Anu V, Golding, Mathew, Koekemoer, Lizbe, Lithgo, Ryan M, Marples, Peter G, Ni, Xiaomin, Thompson, Warren, Wild, Conor, Xavier, Mary-Ann E, Fearon, Daren, von Delft, Frank
• Format: Journal Article
• Language: English
• Published: United States Cold Spring Harbor Laboratory 23.08.2024
• ISSN: 2692-8205; 2692-8205
• DOI: 10.1101/2024.08.23.609196

Chikungunya virus (CHIKV) causes severe fever, rash and debilitating joint pain that can last for months or even years. Millions of people have been infected with CHIKV, mostly in low and middle-income countries, and the virus continues to spread into new areas due to the geographical expansion of its mosquito hosts. Its genome encodes a macrodomain, which functions as an ADP-ribosyl hydrolase, removing ADPr from viral and host-cell proteins interfering with the innate immune response. Mutational studies have shown that the CHIKV nsP3 macrodomain is necessary for viral replication, making it a potential target for the development of antiviral therapeutics. We, therefore, performed a high-throughput crystallographic fragment screen against the CHIKV nsP3 macrodomain, yielding 109 fragment hits covering the ADPr-binding site and two adjacent subsites that are absent in the homologous macrodomain of SARS-CoV-2 but may be present in other alphaviruses, such as Venezuelan equine encephalitis virus (VEEV) and eastern equine encephalitis virus (EEEV). Finally, a subset of overlapping fragments was used to manually design three fragment merges covering the adenine and oxyanion subsites. The rich dataset of chemical matter and structural information discovered from this fragment screen is publicly available and can be used as a starting point for developing a CHIKV nsP3 macrodomain inhibitor.